Stock Events

Stock Events

Reneuron Group 

$0
4
+$0+0% Tuesday 21:00

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
500
Avg. Volume
0
Mkt Cap
62,891.4
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

2DecExpected
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2023
Q2 2025
Q3 2025
-0.06
-0.04
-0.02
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-200.07%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
3.56MRevenue
-7.13MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNUGF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stem
STEM
Mkt Cap164.53M
StemCells, Inc. focuses on cell-based therapeutics, directly competing in the regenerative medicine space similar to Reneuron's focus on stem cell therapies.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap6.74M
Brainstorm Cell Therapeutics Inc. works on stem cell therapies for neurodegenerative diseases, closely aligning with Reneuron's therapeutic areas.
Mesoblast
MESO
Mkt Cap2.14B
Mesoblast Limited develops mesenchymal lineage adult stem cell therapies, competing in the broader regenerative medicine sector alongside Reneuron.
Biolife Solutions
BLFS
Mkt Cap1.34B
BioLife Solutions, Inc. provides bioproduction tools and services, indirectly competing by supporting the cell therapy and regenerative medicine industry.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics, Inc. is involved in the development of programmed cellular immunotherapies, competing in the cell therapy market.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG focuses on gene editing, which represents a broader competition in the field of genetic and cell therapies targeting similar diseases as Reneuron.

About

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Show more...
CEO
Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D
Employees
26
Country
GB
ISIN
GB00BF5G6K95

Listings

OTC Link
US
RNUGF

0 Comments

Share your thoughts

FAQ

What is Reneuron Group stock price today?▼
The current price of RNUGF is $0 USD — it has increased by +0% in the past 24 hours. Watch Reneuron Group stock price performance more closely on the chart.
What is Reneuron Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Reneuron Group stocks are traded under the ticker RNUGF.
What is Reneuron Group market cap?▼
Today Reneuron Group has the market capitalization of 62,891.4
What is Reneuron Group revenue for the last year?▼
Reneuron Group revenue for the last year amounts to 3.56M USD.
What is Reneuron Group net income for the last year?▼
RNUGF net income for the last year is -7.13M USD.
How many employees does Reneuron Group have?▼
As of April 02, 2026, the company has 26 employees.
In which sector is Reneuron Group located?▼
Reneuron Group operates in the Health Care sector.
When did Reneuron Group complete a stock split?▼
The last stock split for Reneuron Group was on January 26, 2018 with a ratio of 1:100.
Where is Reneuron Group headquartered?▼
Reneuron Group is headquartered in Pencoed, GB.